Press Releases June 30, 2026 04:05 PM

Kestra Medical Technologies to Report Fourth Quarter Fiscal 2026 Financial Results on July 14

Kestra Medical Technologies Announces Date for Q4 Fiscal 2026 Earnings Release and Conference Call

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
KMTS

Kestra Medical Technologies, a Nasdaq-listed wearable medical device and digital healthcare company, will release its Q4 fiscal 2026 financial results on July 14, after market close. The company will hold a conference call to discuss the financial results.

Kestra Medical Technologies to Report Fourth Quarter Fiscal 2026 Financial Results on July 14
KMTS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Kestra Medical is scheduled to report its fourth quarter fiscal 2026 earnings on July 14.
  • The company focuses on wearable medical devices and digital healthcare solutions for cardiovascular disease.
  • A conference call and webcast will be held to discuss the financial outcomes.

KIRKLAND, Wash., June 30, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, is scheduled to report fourth quarter fiscal 2026 financial results after the market closes on Tuesday, July 14.

Management will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. A live and archived webcast of the conference call will be available in the “Events” section of the investor relations website.

About Kestra
Kestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com.


Risks

  • Financial results might not meet market expectations leading to stock volatility.
  • Competitive pressures in the wearable medical device and digital healthcare sectors.
  • Reliance on successful integration and innovation of monitoring and therapeutic technologies.

More from Press Releases

Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026 Super League to Report Third Quarter 2026 Financial Results on Monday, November 16, 2026 Nov 12, 2026 UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Nov 4, 2026 BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Nov 4, 2026 Jasper Therapeutics Announces 1-for-30 Reverse Stock Split Nov 4, 2026